Hee Jung Chun, CFO, Director, and 10% Holder, disposed of 1,297,000 Common Shares on a direct ownership basis at prices ranging from $0.667 to $0.715 between April 18th, 2017 and April 24th, 2017. This represents a $892,562 divestment of the company's shares and an account share holdings change of -6.4%.
THC Biomed Intl is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.
THC BioMed Intl Ltd. is a development-stage company. The Company is engaged in the business of scientific research and development, and cultivation of medical marijuana in Canada. The Company produces medical marijuana, cannabis oil and cannabis resin. The Company intends to cultivate medical marijuana and conduct scientific research and development in order to offer products and services through two revenue streams: medical marijuana sales to other Marihuana for Medical Purposes Regulations (MMPR) licensed producers, and products and services related to medical marijuana. It provides a range of services, including consulting, quality assurance training, horticulture training, simulated inspections, record keeping/documenting, physical security plans and analytical services. Its consulting service assists in finding solutions to MMPR related questions. Its horticulture training service provides education in botany basics, plant identification, soil science and nursery techniques.
No Comments